

# Embarking on a New Era for Bladder Cancer Patients

**Monday, 11 September 2017**  
18:30 – 20:00

Satellite Symposium  
Sponsored by MSD

IFEMA, Feria de Madrid  
Tarragona Auditorium Hall 9  
Madrid, Spain

## Educational Objectives

- Educate on the latest advances in immunotherapeutic approaches to metastatic urothelial carcinoma (mUC) with recent data from anti-PD1 and anti-PD-L1 agents, including pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab
- Educate on key learnings in patient management from real-world use of checkpoint inhibitors for mUC
- Generate awareness of PD-(L)1 agents currently under investigation in UC

## AGENDA

18:30 – 18:35	Welcome and Introduction
18:35 – 19:00	Updates on Immunotherapy Data in Metastatic Urothelial Carcinoma
19:00 – 19:25	Real-World Clinical Utilization of Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
19:25 – 19:50	Panel Discussion on Future Perspectives of Immune Checkpoint Inhibitors in Urothelial Carcinoma
19:50 – 19:55	Q&A
19:55 – 20:00	Closing Remarks